Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chiasma, Inc. stock logo
CHMA
Chiasma
$3.76
$4.01
$2.77
$5.74
$217.68M1.282.12 million shs147 shs
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
$10.45
+1.0%
$12.45
$7.21
$16.88
$440.89M0.88721,836 shs114,297 shs
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$9.25
$9.22
$3.46
$9.28
$420.52M1.3840,890 shs178,496 shs
Mallinckrodt plc stock logo
MNK
Mallinckrodt
$0.12
$0.34
$0.75
$6.42
$1.58MN/A2.62 million shs39,227 shs
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$19.45
-0.4%
$18.97
$10.06
$21.72
$366.05M0.8250,186 shs19,325 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chiasma, Inc. stock logo
CHMA
Chiasma
0.00%0.00%0.00%0.00%0.00%
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-7.67%-11.16%-7.01%-19.46%+28.57%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00%0.00%0.00%0.00%0.00%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
0.00%0.00%0.00%0.00%-97.99%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
-1.26%+3.77%-3.70%+9.85%+80.74%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/AN/AN/AN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
4.0871 of 5 stars
3.51.00.04.63.22.50.6
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
1.481 of 5 stars
2.53.00.00.01.81.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
3.00
Buy$26.33151.99% Upside
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$24.0023.39% Upside

Current Analyst Ratings

Latest NATR, MNK, CHMA, KIN, and KALV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/11/2024
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
3/13/2024
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.50 ➝ $24.00
2/14/2024
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $24.00
2/13/2024
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$22.00 ➝ $35.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chiasma, Inc. stock logo
CHMA
Chiasma
$1.11M196.11N/AN/A$1.59 per share2.36
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/AN/AN/AN/A$4.71 per shareN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$42.16M9.97N/AN/A$1.75 per share5.29
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/A$47.48 per shareN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$445.32M0.82$1.57 per share12.39$8.36 per share2.33

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chiasma, Inc. stock logo
CHMA
Chiasma
-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$92.91M-$3.15N/AN/AN/AN/A-86.06%-72.65%7/5/2024 (Estimated)
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/A-$116.19N/AN/A-82.59%20.32%2.49%N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.08M$0.7725.26N/A3.39%12.25%7.75%5/7/2024 (Confirmed)

Latest NATR, MNK, CHMA, KIN, and KALV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/AN/A  
3/12/2024Q4 2023
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A$0.45+$0.45$0.44N/A$108.94 million
3/11/2024Q3 2024
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
-$0.75-$0.84-$0.09-$0.84N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/A
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/A
Mallinckrodt plc stock logo
MNK
Mallinckrodt
N/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chiasma, Inc. stock logo
CHMA
Chiasma
N/A
7.91
7.08
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/A
5.44
5.44
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.19
7.02
7.02
Mallinckrodt plc stock logo
MNK
Mallinckrodt
1.18
0.57
0.31
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.16
1.29

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Chiasma, Inc. stock logo
CHMA
Chiasma
61.68%
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
N/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
66.89%
Mallinckrodt plc stock logo
MNK
Mallinckrodt
83.74%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
79.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Chiasma, Inc. stock logo
CHMA
Chiasma
8557.89 millionN/ANot Optionable
KalVista Pharmaceuticals, Inc. stock logo
KALV
KalVista Pharmaceuticals
11842.19 million37.00 millionOptionable
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
6345.46 millionN/AOptionable
Mallinckrodt plc stock logo
MNK
Mallinckrodt
2,70013.17 million13.13 millionNot Optionable
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
81418.82 million17.94 millionOptionable

NATR, MNK, CHMA, KIN, and KALV Headlines

SourceHeadline
Natures Sunshines Impact Report Highlights Achievements and Continued Commitment Toward SustainabilityNature's Sunshine's Impact Report Highlights Achievements and Continued Commitment Toward Sustainability
prnewswire.com - April 24 at 10:15 AM
Nature’s Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ETNature’s Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ET
finance.yahoo.com - April 23 at 7:40 PM
Natures Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ETNature's Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ET
globenewswire.com - April 23 at 4:05 PM
Those who invested in Natures Sunshine Products (NASDAQ:NATR) five years ago are up 126%Those who invested in Nature's Sunshine Products (NASDAQ:NATR) five years ago are up 126%
finance.yahoo.com - April 21 at 1:52 PM
Natures Sunshine Products, Inc.s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Nature's Sunshine Products, Inc.'s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
finance.yahoo.com - April 4 at 2:56 PM
Natures Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsNature's Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
finance.yahoo.com - March 15 at 7:55 AM
Natures Sunshine Shares Touch 52-Week High After 4Q UpdateNature's Sunshine Shares Touch 52-Week High After 4Q Update
marketwatch.com - March 14 at 8:49 AM
Why Natures Sunshine (NATR) Stock Is Up TodayWhy Nature's Sunshine (NATR) Stock Is Up Today
finance.yahoo.com - March 13 at 1:46 PM
Natures Sunshine Products, Inc.: Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Products, Inc.: Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - March 13 at 7:45 AM
Natures Sunshine: Q4 Earnings SnapshotNature's Sunshine: Q4 Earnings Snapshot
timesunion.com - March 12 at 8:59 PM
Natures Sunshine (NASDAQ:NATR) Misses Q4 Sales TargetsNature's Sunshine (NASDAQ:NATR) Misses Q4 Sales Targets
finance.yahoo.com - March 12 at 8:59 PM
Natures Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 EarningsNature's Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 Earnings
gurufocus.com - March 12 at 6:04 PM
Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
globenewswire.com - March 12 at 4:05 PM
Preview: Natures Sunshine Productss EarningsPreview: Natures Sunshine Products's Earnings
benzinga.com - March 11 at 3:30 PM
Natures Sunshine (NATR) Q4 Earnings: What To ExpectNature's Sunshine (NATR) Q4 Earnings: What To Expect
finance.yahoo.com - March 11 at 10:30 AM
Nature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
finance.yahoo.com - February 20 at 7:35 PM
Natures Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature's Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
globenewswire.com - February 20 at 4:05 PM
Is There Now An Opportunity In Natures Sunshine Products, Inc. (NASDAQ:NATR)?Is There Now An Opportunity In Nature's Sunshine Products, Inc. (NASDAQ:NATR)?
finance.yahoo.com - February 6 at 10:21 AM
Natures Sunshine Products: Unconvincing Trajectory Despite ImprovementsNature's Sunshine Products: Unconvincing Trajectory Despite Improvements
seekingalpha.com - January 31 at 4:43 AM
Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024
finance.yahoo.com - January 2 at 8:03 PM
Natures Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the companyNature's Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the company
finance.yahoo.com - December 21 at 3:09 PM
Nature’s Sunshine Recognized with Best Company Culture AwardNature’s Sunshine Recognized with Best Company Culture Award
finance.yahoo.com - December 19 at 10:07 AM
Natures Sunshine Products Stock (NASDAQ:NATR), Quotes and News SummaryNatures Sunshine Products Stock (NASDAQ:NATR), Quotes and News Summary
benzinga.com - December 12 at 11:35 PM
Nature`s Sunshine Products (NATR) Price Target Increased by 10.26% to 21.93Nature`s Sunshine Products (NATR) Price Target Increased by 10.26% to 21.93
msn.com - November 27 at 7:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Chiasma logo

Chiasma

NASDAQ:CHMA
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.
KalVista Pharmaceuticals logo

KalVista Pharmaceuticals

NASDAQ:KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Kindred Biosciences logo

Kindred Biosciences

NASDAQ:KIN
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
Mallinckrodt logo

Mallinckrodt

NYSE:MNK
Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.
Nature

Nature's Sunshine Products

NASDAQ:NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.